Articles tagged "Heart transplant patients"

2016 American Transplant Congress
Four-Factor Prothrombin Complex Concentrate as a Strategy to Rapidly Reverse Anticoagulation in Patients Undergoing Cardiac Transplantation: Better Than the Conventional Approach?
T. Sam,¹ G. Gonzalez-Stawinski,² G. Saracino,³ A. Jamil,³ S. Hall,² K. Cox,¹ B. Lima.²
¹Department of Pharmacy, Baylor University Medical Center, Dallas, TX; ²Heart Transplantation and Mechanical Circulatory Support, Baylor University Medical Center, Dallas, TX; ³Baylor Research Institute, Baylor University Medical Center, Dallas, TX.
PurposeThe purpose of this analysis is to compare outcomes of administering four-factor prothrombin complex concentrate (4F-PCC, Kcentra™) versus standard of care for anticoagulation reversal in…
2016 American Transplant Congress
The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation.
O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.
University of British Columbia, Vancouver, BC, Canada.
BackgroundOrthotopic heart transplantation (OHT) is the gold standard for the management of select patients with end-stage heart failure, but limited by an ongoing organ donor…
2016 American Transplant Congress
Using Gastrointestinal Biopsy to Predict Outcome in Patients Evaluated for Cardiac Transplantation for Amyloidosis: A Report from the International Consortium on Cardiac Amyloidosis Transplantation (iCCAT).
Y. Li,¹ K. Verkouw,¹ S. Tabtabai,¹ R. Barrios,² R. Gill,³ J. Koo,⁴ C. Marboe,⁵ E. Rodriguez,⁶ C. Tan,⁶ T. De Marco,³ J. Estep,² M. Hanna,⁶ M. Maurer,⁵ J. Patel,⁴ V. Selby,³ M. Semigran,¹ J. Stone.¹
¹Massachusetts General Hospital, Boston, MA; ²The Methodist Hospital, Houston, TX; ³University of California San Francisco, San Francisco, CA; ⁴Cedars-Sinai Heart Institute, Los Angeles, CA; ⁵Columbia University Medical Center, New York, NY; ⁶Cleveland Clinic, Cleveland, OH.
Heart transplant (HT) is an established therapy for heart failure due to amyloidosis. The utility of gastrointestinal (GI) biopsy in predicting patient outcomes and guiding…
2016 American Transplant Congress
Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and Immuno-Regulatory miRNA Induce Graft Rejection.
M. Sharma,^1,2 M. Gunasekaran,^1,2 Z. Xu,^1,2 N. Steward,¹ W. Liu,^1,2 N. Benshoff,¹ T. Mohanakumar.^1,2
¹Washington Univ Sch Med, St. Louis, MO; ²Norton Thoracic Institute - St. Joseph's Hospital, Phoenix, AZ.
Heart transplantation (HTx) remains an option for patients with cardiac diseases. However, humoral and cell mediated immune responses represent a major obstacle for long-term survival.…
2016 American Transplant Congress
Air Pollution – An Additional Risk Factor for Developing Cardiac Allograft Vasculopathy.
C. Bara, D. Böthig, Y. Scheibner, D. Bobylev, B. Przybylek, A. Haverich.
Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Purpose:Cardiac allograft vasculopathy (CAV) remains one of the primary causes of death in long-term follow-up after heart transplantation (HTx) and is the most limiting factor…
2016 American Transplant Congress
Impact of Transfusion Requirements on Likelihood of Heart Transplantation After Total Artificial Heart.
J. Cook,¹ L. Kang,¹ M. Flattery,² I. Tchoukina.²
¹Internal Medicine, Virginia Commonwealth University, Richmond, VA; ²Pauley Heart Center, Virginia Commonwealth University, Richmond, VA.
Background:Total artificial heart (TAH) is used as a bridge to heart transplantation in patients with end-stage biventricular failure. Anemia requiring blood transfusions occurs following TAH…
2016 American Transplant Congress
The Role of Palliative Care in the Thoracic Transplant Multidisciplinary Care Team: Barriers and Benefits.
A. Manfredi,¹ C. Toevs.²
¹Loyola University Medical Center, Maywood, IL; ²Terre Haute Regional Hospital, Terre Haute, IN.
PURPOSE: Patients under consideration for or who have undergone lung and heart transplantation experience many symptoms, including dyspnea, anxiety, pain and caregiver burden. Integration of…
2015 American Transplant Congress
Evaluating the Benefits of Everolimus on Cardiac Allograft Vasculopathy: Further Evidence from Results of Imputations for Missing IVUS Data from A2310 Study
P. Lopez,¹ G. Dong,² Z. Wang.²
¹Novartis Pharma AG, Basel, Switzerland; ²Novartis Pharmaceuticals, East Hanover, NJ; ³Novartis Pharmaceuticals, East Hanover, NJ.
Purpose: A2310 IVUS study showed that everolimus (EVR) provides cardiac allograft vasculopathy (CAV) benefit compared to mycophenolate mofetil (MMF) by assessing the mean change in…
2015 American Transplant Congress
Biomarker Panel Profile for Identification of High-Risk Patients After Heart Transplantation
M. Barten,¹ M.-T. Dieterlen,² J. Garbade,² F. Mohr.²
¹Cardiovascular Surgery, Universisty Heart Center Hamburg, Hamburg, Germany; ²Cardiac Surgery, University Leipzig Heart Center, Leipzig, Germany.
Background: The first year after cardiac transplantation is critical for transplant survival and long-term outcome. Identification of suitable biomarkers for detection of rejection processes is…
2015 American Transplant Congress
Incidence, Determinants and Outcome of Kidney Transplantation for End Stage Renal Disease After Heart Transplantation
A. Grupper,¹ A. Grupper,¹ R. Daly,¹ M. Hathcock,² W. Kremers,² F. Cosio,¹ B. Edwards,¹ S. Kushwaha.¹
¹William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN; ²Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Objectives: Progressive renal failure is a frequent complication following heart transplantation (HTx), is generally attributed to calcineurin inhibitor (CNI) based immunosuppression, and may result in…